CADL Reports $194.8M Cash, Advances Aglatimagene Phase 3, Q1 2026 Update
Candel Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $8.51
-14% in 3d after detection
Post-detection moves
1h
—
1d
-1.6%
3d
-14%
7d
-11%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS